Opdualag is a first-in-class, fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor nivolumab and novel LAG-3-blocking antibody relatlimab
The study looked at 1,364 children in Arizona, Florida, Texas, and Utah who submitted weekly nasal swabs and surveys from July 2021 through February 2022, regardless of whether they had symptoms
As the world celebrates World Glaucoma Week (March 7-13th), Nikkhil K Masurkar, Executive Director, Entod Pharmaceuticals, an authority on eye diseases spoke to Thomas C Thottathil, Editor, indianpharmapost.com, on the seriousness of Glaucoma
SAATH is a ‘One AXA’ public health initiative between AXA France Vie, AXA GO Business Operations, and AXA XL
New results build on previously reported significant recurrence-free survival (rfs) benefit seen in these patients
Covaxin is not approved in the USA for any age group
It is a Phase 3 ready anti-myostatin adnectin for Spinal Muscular Atrophy (SMA).
The first wave of shipments includes several countries, such as Germany, France and Austria
New biotechnology product aims to be world's fastest automatic sanitary solution
Immune responses were about two-to-three-fold higher in adolescents than in adults against all variants studied. Vaccine was well-tolerated with no safety signals identified
Subscribe To Our Newsletter & Stay Updated
